Archives

An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies

Kanchana Ravichandran, Erwan LeScolan, Na Cai, Bruce Howng, Robert Lau, Lisa Clark, Joshua Millet, Pankaj Kumar, Sushma Gurumurthy, Raghava Sriramaneni, Sean McAllister, Vangipuran Rangan, Olga Vasiljeva, Madan Paidhungat, Dylan Daniel, Marcia Belvin, Lin Guey. Presented at the American Association for Cancer Research Annual Meeting, April 28, 2025.

Learn More

Conditionally activated IFNa induces an inflammatory tumor microenvironment in preclinical models and increases efficacy in combination with checkpoint blockade

Benjamin Povinelli, Kamaljeet Kaur, Alexey Berezhnoy, Hsin Wang, Na Cai, Nicole Lapuyade, Carol LePage, Michael Winter, Olga Vasiljeva, Madan Paidhungat, Vangipuram Rangan, Erwan Le Scolan, Leila Boustany, Marcia Belvin and Dylan Daniel. Presented at SITC 2023, November 1-5, 2023, San Diego, CA.

Learn More

Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor

Marcia Belvin Ph.D. Presented at World ADC, October 16-19, 2023, San Diego, California.

Learn More

Designing Conditionally Activated Probody® Cytokines to Localize Antitumor Activity to Cancers

Dylan Daniel, Ph.D., Presented at the American Association of Immunologists Annual Meeting, May 13, 2023.

Learn More

Results of a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

Kathy Miller, Sara M. Tolaney, Leisha Emens, Sung-Bae Kim, Erika Hamilton, Cristina Saura, Lucia Sanz, Valentina Boni, Filipa Lynce, Juan M. Cejalvo, Jennifer A. Crozier, Shirley Wang, Shannon Tsai, Hojjat Bazzazi, Hirdesh Uppal, Alison Hannah, Sara Hurvitz. Poster presented at the San Antonio Breast Cancer Symposium®, December 6-10, 2022.

Learn More

CX-801, Conditionally Activatable Interferon-alpha 2b Improves Tolerability and Exhibits Preferential Activity in Tumors

Alexey Berezhnoy, Ph.D., Presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), November, 8th, 2022.

Learn More

Tailoring the Selection of Target, Payload, and Tumor Type to Maximize the Therapeutic Index of Conditionally Activated ADCs

Marcia Belvin, SVP, Head of Research

Learn More

Conditional PD-1/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti–PD 1/PD-L1 agents

Assi HH, Wong C, Tipton KA, et.al. Cancer Immunol Res. October 11 2021. DOI: 10.1158/2326-6066.CIR-21-0031

Learn More

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Sanborn RE, Hamid O, de Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002446. doi: 10.1136/jitc-2021-002446

Learn More

CX-072 (pacmilimab), a Probody®️ PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Naing A, Thistlethwaite F, De Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002447. doi: 10.1136/jitc-2021-002447

Learn More